More than 600 life sciences companies operate inside a single square mile of Cambridge. Kendall Square and its surrounding cluster employ roughly 118,000 people directly in biopharma roles, with another 182,000 supported indirectly, together accounting for close to 18% of the entire Massachusetts economy. By reputation, and by those numbers, it's the most concentrated biotech hub on Earth.
Two other things are also true right now, and they point in opposite directions.
The Downturn Is Real, and It's Hitting Real Companies
By the fourth quarter of 2025, life-science lab vacancy across the greater Boston metro area hit an all-time high of 28%, according to CBRE, with total available lab space reaching a record 17 million square feet. Include sublease space, companies trying to offload space they're no longer using, and overall availability climbs to nearly 30%.
This isn't abstract. Takeda, the largest biopharmaceutical employer in Massachusetts, filed notice this year that it will lay off 247 employees at its Kendall Square headquarters as part of a board-approved restructuring, with cuts beginning in July. Seres Therapeutics announced a 30% workforce reduction. Thermo Fisher Scientific cut nearly 300 employees across its Cambridge and Plainville offices. A funding environment that once flowed freely into Kendall Square startups has slowed considerably, and PhD graduates who once expected a straightforward path into the sector are increasingly running into hiring freezes instead.
By any conventional read, this is an industry in contraction.
And Yet the Actual Center of the Cluster Is Still Essentially Full
Here's where it stops being a simple story. That record 28% vacancy figure describes the broader Boston metro, not Kendall Square itself. Inside the actual square mile, Class A lab space has been effectively at zero vacancy for more than a year. Incubators like LabCentral and CIC, the first stop for many early-stage biotech companies, report 98% occupancy with waitlists exceeding twelve months. Takeda itself, even while cutting Kendall Square headcount, recently leased roughly 600,000 additional square feet nearby to consolidate its R&D operations. Vertex Pharmaceuticals anchors 1.4 million square feet across the harbor in the Seaport, and that district alone has absorbed 1.2 million square feet of new lab development since 2023.
So the honest picture isn't "Boston biotech is struggling" or "Boston biotech is booming." It's a two-tier market: older or less centrally located lab space is sitting empty at record rates, while the actual physical and reputational core, Kendall Square proper, remains as saturated and competitive as ever.
The Same Split Shows Up in Hiring, Not Just Real Estate
Layer hiring on top of real estate and the picture sharpens further. Even amid broad industry layoffs, recruiters report that specific, highly specialized disciplines, cell and gene therapy manufacturing, AI-enabled drug discovery, and CMC regulatory affairs among them, have candidate-to-role ratios so imbalanced that conventional hiring approaches have stopped working. The industry isn't uniformly cutting or uniformly hiring. It's doing both simultaneously, sorted by specialization, not by headline sentiment.
What This Means If You're Networking in Boston Biotech Right Now
"Boston biotech is down" and "Boston biotech is up" are both incomplete on their own. The honest version is that the industry is bifurcating, by real estate tier, by specialization, and increasingly by which specific 600 companies you're talking about inside that one square mile. A blanket read on the sector, in either direction, will be wrong about a meaningful share of the people actually working in it.
The people who know which tier you're in are more valuable than any industry-wide headline. With vacancy and hiring diverging this sharply by sub-sector and specific address, a real conversation with someone actually working in cell and gene therapy manufacturing right now tells you more than any regional vacancy report or layoff headline.
Broad "biotech is struggling" narratives may be quietly discouraging exactly the specialists who are in shortest supply. If a talented CMC regulatory affairs candidate reads the Takeda layoff headline and assumes the whole field is contracting, that's a real cost, both to them and to the companies who can't find enough people in exactly that discipline.
Kendall Square isn't simply thriving or simply struggling. It's sorting itself, in real time, into who has room and who doesn't, and the only reliable way to know which side of that sort you're standing on is to actually talk to the people working inside it.
NetworkNite's format puts you across the table from people working inside specific companies and disciplines, the kind of real, current read a vacancy report or layoff headline can't give you. See how it works →